This study investigates the cooperative effects of *BRAF*^V600E^ and *PTEN* silencing in the development of metastatic melanoma. Mice with conditional melanocyte-specific expression of *BRAF*^V600E^ developed benign melanocytic hyperplasias but did not progress to melanoma over 15-20 months. However, when *BRAF*^V600E^ was combined with *PTEN* tumor suppressor gene silencing, it led to 100% penetrance of melanoma with short latency and metastases in lymph nodes and lungs. Melanoma was prevented by inhibitors of mTORC1 (Rapamycin) or MEK1/2 (PD325901), but the melanoma recurred upon cessation of drug administration, indicating the presence of long-lived melanoma-initiating cells. Combined treatment with Rapamycin and PD325901 significantly reduced established melanoma size. This mouse model, which recapitulates key features of human melanoma, provides a valuable tool for studying melanoma metastasis and evaluating agents for preventing or treating metastatic disease.This study investigates the cooperative effects of *BRAF*^V600E^ and *PTEN* silencing in the development of metastatic melanoma. Mice with conditional melanocyte-specific expression of *BRAF*^V600E^ developed benign melanocytic hyperplasias but did not progress to melanoma over 15-20 months. However, when *BRAF*^V600E^ was combined with *PTEN* tumor suppressor gene silencing, it led to 100% penetrance of melanoma with short latency and metastases in lymph nodes and lungs. Melanoma was prevented by inhibitors of mTORC1 (Rapamycin) or MEK1/2 (PD325901), but the melanoma recurred upon cessation of drug administration, indicating the presence of long-lived melanoma-initiating cells. Combined treatment with Rapamycin and PD325901 significantly reduced established melanoma size. This mouse model, which recapitulates key features of human melanoma, provides a valuable tool for studying melanoma metastasis and evaluating agents for preventing or treating metastatic disease.